HCA Healthcare price target raised to $290 from $270 at Truist

Truist analyst David MacDonald raised the firm’s price target on HCA Healthcare to $290 from $270 and keeps a Buy rating on the shares. The company posted "solid" Q4 results amid improving labor trends, continued favorable payor mix/acuity and solid volumes, the analyst tells investors in a research note. HCA’s 2023 guide also suggests that the company’s underlying trends remain solid, and the firm view the company as "well positioned to drive continued labor improvement", with its management’s long-term investments supporting further growth and efficiencies.